<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477073</url>
  </required_header>
  <id_info>
    <org_study_id>GEXGP24102</org_study_id>
    <nct_id>NCT01477073</nct_id>
  </id_info>
  <brief_title>Multiple Dose FSH-GEX(TM) in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Mono-center, Placebo and Comparator Controlled, Single-blind, Randomized, Parallel Group, Clinical Study to Determine Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FSH-GEX(TM) Administered Subcutaneously in Healthy Pituitary-suppressed Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glycotope Biotechnology GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is the pharmacokinetic and pharmacodynamic characterization of a&#xD;
      multiple dose administration of FSH-GEX™ in healthy pituitary-suppressed female volunteers,&#xD;
      in comparison with two marketed comparator products or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy pituitary-suppressed female subjects received multiple doses of FSH-GEX at one of 2&#xD;
      different dose levels (75 IU and 150 IU dosing once daily (QD), or 150 IU (dosing once every&#xD;
      other day (QAD)) for maximal 7 Days. They were compared with subjects who received a urinary&#xD;
      FSH or a recombinant FSH or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of FSH-GEX™ following multiple dose administration by subcutaneous injection</measure>
    <time_frame>43 days</time_frame>
    <description>frequency of dose related adverse events, measurement of vital signs, body measurements, transvaginal ultrasound, ECG and laboratory values in comparison to placebo and the two comparators with marketing authorization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic profile of FSH-GEX™ following multiple dose administration by subcutaneous injection (part 1)</measure>
    <time_frame>28 time points up to 14 days post-dose</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic profile of FSH-GEX™ following multiple dose administration by subcutaneous injection (part 2)</measure>
    <time_frame>28 time points up to 14 days post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic parameters of FSH-GEX™ following multiple dose administration by subcutaneous injection</measure>
    <time_frame>17 time points up to 14 days post-dose</time_frame>
    <description>Estradiol (E2), Luteinizing Hormone (LH) and inhibin B serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic parameters of FSH-GEX™ following multiple dose administration by subcutaneous injection</measure>
    <time_frame>9 time points up to14 days post-dose</time_frame>
    <description>follicular response and endometrial thickness as determined by transvaginal ultrasonography</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Female Infertility</condition>
  <arm_group>
    <arm_group_label>FSH-GEX 75 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>follitropin epsilon 75 IU QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH-GEX 150 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>follitropin epsilon 150 IU QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH-GEX 150 IU QAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>follitropin epsilon 150 IU QAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>recombinant FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gonal-f 150 IU QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>urinary FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bravelle 150 IU QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH-GEX™</intervention_name>
    <arm_group_label>FSH-GEX 150 IU</arm_group_label>
    <arm_group_label>FSH-GEX 150 IU QAD</arm_group_label>
    <arm_group_label>FSH-GEX 75 IU</arm_group_label>
    <other_name>follitropin epsilon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant FSH</intervention_name>
    <arm_group_label>recombinant FSH</arm_group_label>
    <other_name>Gonal-f</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>urinary FSH</intervention_name>
    <arm_group_label>urinary FSH</arm_group_label>
    <other_name>Bravelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects from 18-40 years of age at screening.&#xD;
&#xD;
          2. Subjects must be in good health as determined by medical and gynecological history,&#xD;
             physical and gynecological examination, vital signs, body measurements,&#xD;
             electrocardiogram, and laboratory tests&#xD;
&#xD;
          3. Subjects must be willing to use additional non-hormonal contraception&#xD;
&#xD;
          4. Subjects must have used a combined oral contraceptive, combined contraceptive vaginal&#xD;
             ring or combined contraceptive patch&#xD;
&#xD;
          5. Vital signs which are within the following ranges: systolic blood pressure between&#xD;
             90-140 mmHg, diastolic blood pressure between 50-90 mmHg, pulse rate between 40 - 100&#xD;
             bpm&#xD;
&#xD;
          6. Subjects must have a body weight of minimally 50.0 kg with a BMI between 18.0 and 29.9&#xD;
             kg/m2&#xD;
&#xD;
          7. Able to provide written informed consent prior to study participation.&#xD;
&#xD;
          8. Able to communicate well with the investigator and to understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Smokers of more than 5 cigarettes per day.&#xD;
&#xD;
          2. Average daily intake of more than 3 units of alcohol per day (where 1 unit equals 250&#xD;
             mL of beer, 125 mL of wine or 25 mL of spirits) or an average weekly intake of more&#xD;
             than 21 units alcohol.&#xD;
&#xD;
          3. Use of any prescription drug or over-the-counter medication from screening until the&#xD;
             end-of-study visit, without prior approval of the investigator. Paracetamol® is&#xD;
             acceptable without prior approval.&#xD;
&#xD;
          4. Any drugs that may reduce the effectiveness of combination oral contraceptive (COC)&#xD;
             from screening until the end-of-study visit&#xD;
&#xD;
          5. Administration of any investigational product or use of any investigational device&#xD;
             within 30 days prior to Screening.&#xD;
&#xD;
          6. Donation or loss of 500 mL or more of blood within 90 days prior to first dosing of&#xD;
             FSH-GEX(TM).&#xD;
&#xD;
          7. History of acute or chronic bronchospastic disease&#xD;
&#xD;
          8. History of allergies for drugs, seafood, nuts, eggs, wasp-stings; history of atopic&#xD;
             allergy. A known hypersensitivity to any of the study drugs.&#xD;
&#xD;
          9. Any surgical or medical condition which might alter the absorption, distribution,&#xD;
             metabolism, or excretion of drugs or which may jeopardize the subject in case of&#xD;
             participation in the study.&#xD;
&#xD;
         10. History or presence of any malignancy.&#xD;
&#xD;
         11. Determined or suspected pregnancy.&#xD;
&#xD;
         12. Breast feeding women.&#xD;
&#xD;
         13. History of (or current) endocrine abnormalities&#xD;
&#xD;
         14. Contraindication for the use of oral contraceptives&#xD;
&#xD;
         15. Contraindication for the use of follitropin alfa, follicle-stimulating hormone (FSH)&#xD;
             or any of the excipients (hypersensitivity to follitropin alfa, FSH or any of the&#xD;
             excipients; tumors of the hypothalamus or the pituitary gland; ovarian enlargement or&#xD;
             cyst not due to polycystic ovarian disease; gynecological bleeding of unknown origin;&#xD;
             ovarian, uterine, or mammary carcinoma).&#xD;
&#xD;
         16. Porphyria or family history of porphyria.&#xD;
&#xD;
         17. History of ovarian surgery.&#xD;
&#xD;
         18. Any ovarian or abdominal abnormality that would interfere with adequate ultrasound&#xD;
             investigation.&#xD;
&#xD;
         19. An abnormal cervical smear&#xD;
&#xD;
         20. History or presence of an immune-compromising disease, or a positive human&#xD;
             immunodeficiency virus (HIV) test result in the past or at the screening visit.&#xD;
&#xD;
         21. History of Hepatitis B or C, or a positive Hepatitis B surface antigen (HBsAg) or&#xD;
             Hepatitis C test result at the screening visit.&#xD;
&#xD;
         22. History of drug or alcohol abuse within the 12 months prior to the screening visit or&#xD;
             evidence of such abuse&#xD;
&#xD;
         23. Planned surgery or hospitalization during the period of the study.&#xD;
&#xD;
         24. Concurrent participation or participation within 30 days before screening in another&#xD;
             clinical trial, or participation in more than 3 clinical studies within 12 months,&#xD;
             prior to the expected date of enrolment into the study or previous participation in&#xD;
             the 104676-CS0160 (FSH-GEXTM) study.&#xD;
&#xD;
         25. Injection of one or more doses of any depot contraceptive drug /drug combination ≤10&#xD;
             months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glycotope GmbH Director</last_name>
    <role>Study Director</role>
    <affiliation>Glycotope GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Abd-Elaziz K, Duijkers I, Stöckl L, Dietrich B, Klipping C, Eckert K, Goletz S. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials. Hum Reprod. 2017 Aug 1;32(8):1639-1647. doi: 10.1093/humrep/dex220.</citation>
    <PMID>28591833</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in-vitro fertilization</keyword>
  <keyword>reproductive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

